放疗免疫调节效应研究的进展——从基础到临床

王妤, 毕楠

  1. 国家癌症中心,国家肿瘤临床医学研究中心,中国医学科学院/北京协和医学院肿瘤医院放疗科,北京 100021
  • 收稿日期:2023-08-17 修回日期:2023-10-24 出版日期:2023-12-30 发布日期:2023-12-28
  • 通信作者: 毕 楠(ORCID: 0000-0001-7201-2930),主任医师。
  • 作者简介:王 妤(ORCID: 0009-0008-1769-9387),在读博士研究生,住院医师。

摘要/Abstract

摘要:

既往观点认为,放射治疗主要通过破坏肿瘤细胞脱氧核糖核酸双链直接发挥杀伤肿瘤细胞的作用,近年来研究发现,放疗也可通过上调局部与全身免疫反应,间接产生积极有效的抗肿瘤免疫应答。然而,放疗的免疫调节效应具有双面性,一方面可激活并产生抗肿瘤免疫促进效应,另一方面也可能产生免疫抑制作用。其中,放疗正向调节适应性与固有性抗肿瘤免疫反应的关键分子机制主要包括:诱导免疫原性细胞凋亡从而促进T淋巴细胞的增殖与活化;激活环磷酸鸟苷-腺苷合成酶-干扰素基因刺激蛋白通路引发Ⅰ型干扰素反应;改变肿瘤细胞表型,加强其免疫原性与抗原可视度;刺激肿瘤细胞与基质细胞释放多种炎症因子,重塑肿瘤免疫微环境;上调肿瘤细胞表面免疫检查点以及死亡受体等的表达,促进免疫识别与抗肿瘤免疫应答。而放疗负向抑制免疫反应的主要机制包括:诱导肿瘤细胞上调多种免疫抑制因子的基因表达;增强包括调节性T细胞、髓系来源抑制性细胞在内的多种免疫抑制细胞的功能与作用;导致淋巴细胞的数量减少以及免疫效应细胞的耗竭等。基于以上关于放疗免疫调节效应的机制原理探索,目前在放疗联合免疫治疗的临床实践中也显示出重大的研究进展,包括免疫治疗时代背景下的放疗远隔效应,即放疗照射野以外产生的有效抗肿瘤免疫应答,以及立体定向放疗或低剂量放疗联合免疫检查点抑制剂治疗时显著增加的疗效获益。然而,目前对于放疗联合免疫治疗产生的协同作用机制及其具体影响因素等仍不明确,未来需要在放疗与免疫治疗联合治疗的最佳放疗剂量、放疗分割模式、放疗照射部位与靶区设计、免疫药物选择以及放疗与免疫联合治疗顺序等研究方向开展深入探索,以进一步提高临床疗效,促进放疗免疫调节生物学效应的临床转化应用。本文将对放疗的免疫调节效应以及放疗与免疫治疗联合协同作用的基础与临床研究最新进展进行系统综述,以期为放疗联合免疫治疗的理论基础发展与临床实践进步提供参考。

关键词: 放射治疗, 免疫调节, 免疫检查点抑制剂, 远隔效应

Abstract:

Previously, radiotherapy was considered to directly kill tumor cells by deoxyribonucleic acid double-strand break. Recent studies have found that radiotherapy can also produce positive and effective anti-tumor effect by upregulating local and systemic immune responses. However, the immunomodulatory effect of radiotherapy is double-sided. On the one hand, it can activate anti-tumor immune-promoting effect, on the other hand, it may also produce immunosuppressive effect. The key molecular mechanisms of the positive regulation of adaptive and innate anti-tumor response by radiotherapy primarily include: induction of immunogenic cell death to promote the proliferation and activation of T lymphocytes; activation of the cyclic GMP-AMP synthase-stimulator of interferon genes pathway to induce type Ⅰ interferon response; changing the phenotype of tumor cells to enhance their immunogenicity and antigen visibility; stimulating tumor cells and stromal cells to release a variety of inflammatory factors and reshape the tumor immune microenvironment; upregulating the expression of immune checkpoint and death receptor on the surface of tumor cells to promote immune recognition and anti-tumor immune response. In addition, the mechanisms of negative immune suppression by radiotherapy mainly include: induction of tumor cells to upregulate the gene expression of multiple immunosuppressive factors; enhancing the function and effect of various immunosuppressive cells, including regulatory T cells and myeloid-derived suppressor cells; leading to the decreased number of lymphocytes and the depletion of immunologic effector cells. Based on the above exploration of the mechanisms and principle of the immunomodulatory effect of radiotherapy, significant progress has also been shown in the clinical practice of combining radiotherapy with immunotherapy, such as the abscopal effect in the context of immunotherapy era, that is, the effective anti-tumor immune responses generated outside the irradiation field of radiotherapy, as well as the increased efficacy benefit when stereotactic body radiation therapy or low-dose radiotherapy combined with immune checkpoint inhibitors. However, at present, the synergistic mechanism of radiotherapy plus immunotherapy and its influencing factors are unclear. In the future, more in-depth investigations on optimal radiotherapy dose, segmentation regimens, irradiation sites and target volume design, immunotherapy agent selection and the sequence of combining radiotherapy with immunotherapy are necessary, in order to further improve efficacy and promote the translational application of immunomodulatory biological effects of radiotherapy. This article systematically reviewed the latest advancements of basic and clinical research on the immunomodulatory effect of radiotherapy and the synergy of combing radiotherapy with immunotherapy, aiming to provide guidance on the development of theoretical basis and clinical practice regarding the combination of radiotherapy and immunotherapy.

Key words: Radiotherapy, Immunomodulatory, Immune checkpoint inhibitor, Abscopal effect

中图分类号: 

相关文章

[1] 吴晗, 杨章孺, 冯雯, 曾琬琴, 郭金栋, 李洪选, 王常禄, 王家明, 吕长兴, 张琴, 余雯, 蔡旭伟, 傅小龙. 多原发性早期肺癌立体定向放射治疗后疗效及患者预后分析[J]. 中国癌症杂志, 2023, 33(9): 844-856.
[2] 张皓婷, 郑静, 傅梦姣, 周建英. 免疫治疗肺癌诱发甲状腺功能异常的研究进展[J]. 中国癌症杂志, 2023, 33(7): 701-706.
[3] 左学良, 陈志强, 董润雨, 王智雄, 蔡娟. 联合检测LDHA和PD-L1在晚期胃癌PD-1抑制剂疗效预测及预后评估中的价值[J]. 中国癌症杂志, 2023, 33(5): 460-468.
[4] 唐天赐, 翟周诗佳, 李省苇, 王孝深, 倪晓晨. 广义等效均匀剂量优化方法在鼻咽癌调强放射治疗计划中的应用研究[J]. 中国癌症杂志, 2023, 33(3): 274-281.
[5] 周腾, 张剑. 2023年ESMO乳腺癌治疗最新进展[J]. 中国癌症杂志, 2023, 33(11): 981-988.
[6] 中国抗癌协会肿瘤内分泌专业委员会. 妇科恶性肿瘤免疫治疗中国专家共识(2023年版)[J]. 中国癌症杂志, 2023, 33(10): 954-967.
[7] 庄晗, 凌池芳, 王佳舟, 韩序, 姜睿, 胡伟刚. 局部晚期胰腺癌75 Gy同步加量放射治疗的剂量可行性研究[J]. 中国癌症杂志, 2023, 33(1): 54-60.
[8] 许宇辰, 程蕾蕾, 王妍, 林瑾仪, 陈佳慧, 陈怡帆, 周宇红, 刘天舒, 葛均波. sST2在免疫检查点抑制剂相关不良反应风险预测中的价值[J]. 中国癌症杂志, 2022, 32(8): 712-718.
[9] 蔡钢, 王舒蓓, 陈佳艺. 放射治疗在胃癌全程管理中的现状与挑战[J]. 中国癌症杂志, 2022, 32(7): 581-587.
[10] 陈怡帆, 程蕾蕾, 沈毅辉, 张卉, 汪雪君, 许宇辰, 葛均波. 程序性死亡[蛋白]-1抑制剂诱导小鼠心肌炎模型的建立[J]. 中国癌症杂志, 2022, 32(7): 606-613.
[11] 吴建辉, 储香玲, 王李强, 林心情, 谢晓鸿, 谢梦青, 赵静, 邓海怡, 杨伊霖, 邱桂焕, 周茂林, 孙霓, 李茹, 陈萤, 邓佳茜, 曾晨, 潘柏林, 秦茵茵, 刘明, 苏春霞, 周承志. 中国肺癌患者真实世界免疫检查点抑制剂相关性肺炎的流行病学分析[J]. 中国癌症杂志, 2022, 32(6): 469-477.
[12] 苏春霞, 周彩存. 晚期非小细胞肺癌免疫治疗现状及未来方向[J]. 中国癌症杂志, 2022, 32(6): 478-486.
[13] 虞思来, 倪建佼, 朱正飞. 免疫治疗时代不可手术局部晚期非小细胞肺癌的治疗:现状与展望[J]. 中国癌症杂志, 2022, 32(6): 487-498.
[14] 江健韵, 应红梅. BRAF V600突变阳性的晚期黑色素瘤治疗的临床研究进展[J]. 中国癌症杂志, 2022, 32(5): 445-450.
[15] 徐晓飞, 张丽霞, 代贺阳, 陈凌云, 薛姣姣, 李庆霞. 整体纵向应变评估乳腺癌放疗所致心脏毒性的价值:系统综述和meta分析[J]. 中国癌症杂志, 2022, 32(10): 971-978.